×
Demant Receivables 2012-2023 | WILYY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Demant receivables for the quarter ending December 31, 2023 were
$0.646B
, a
3.61% increase
year-over-year.
Demant receivables for 2023 were
$0.646B
, a
6.22% increase
from 2022.
Demant receivables for 2022 were
$0.609B
, a
5.17% decline
from 2021.
Demant receivables for 2021 were
$0.642B
, a
22.39% increase
from 2020.
View More
Demant Receivables 2012-2023 | WILYY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Demant receivables for 2023 were
$0.646B
, a
6.22% increase
from 2022.
Demant receivables for 2022 were
$0.609B
, a
5.17% decline
from 2021.
Demant receivables for 2021 were
$0.642B
, a
22.39% increase
from 2020.
Related Stocks
Company Name
Market
Cap
Abbott Laboratories (ABT)
$202.2B
Stryker (SYK)
$143.3B
Boston Scientific (BSX)
$130.1B
Medtronic (MDT)
$112.5B
EssilorLuxottica (ESLOY)
$111.7B
Lonza Group Ag (LZAGY)
$45.4B
Haleon (HLN)
$43.5B
GE HealthCare Technologies (GEHC)
$39.3B
ResMed (RMD)
$37B
Terumo (TRUMY)
$29.6B
Koninklijke Philips (PHG)
$25B
Zimmer Biomet Holdings (ZBH)
$21.5B
Insulet (PODD)
$18.8B
Baxter (BAX)
$17.7B
Smith & Nephew SNATS (SNN)
$10.6B
Bio-Rad Laboratories (BIO)
$10.3B
BellRing Brands (BRBR)
$9.1B
Lantheus Holdings (LNTH)
$6.1B
Haemonetics (HAE)
$4.5B
TG Therapeutics (TGTX)
$4.5B
ICU Medical (ICUI)
$4.3B
Prestige Consumer Healthcare (PBH)
$4B
Perrigo (PRGO)
$3.6B
Neogen (NEOG)
$3.5B
Envista Holdings (NVST)
$3.5B
Agios Pharmaceuticals (AGIO)
$3.4B
GN Store Nord (GNNDY)
$3B
Shandong Weigao Medical Polymer (SHWGF)
$3B
QuidelOrtho (QDEL)
$2.9B
LeMaitre Vascular (LMAT)
$2.3B